This is the peer reviewed version of the following article:

rs7903146 Polymorphism at Transcription Factor 7 Like 2 Gene Is Associated with Total Cholesterol and Lipoprotein Profile in HIV/Hepatitis C Virus-Coinfected Patients


AIDS Res Hum Retroviruses. 2015 Mar;31(3):326-34.

which has been published in final form at https://doi.org/10.1089/aid.2014.0195
Original Article

Title: rs7903146 polymorphism at transcription factor 7 like 2 gene is associated with total cholesterol and lipoprotein profile in HIV/HCV-coinfected patients

Running head: TCF7L2 polymorphism and lipid profile

Authors: Daniel PINEDA-TENOR 1, Juan BERENGUER 2,3, María A JIMÉNEZ-SOUS A 1, Ana CARRERO 2,3, Mónica GARCÍA-ÁLVAREZ 1, Teresa ALDÁMIZ-ECHEVARRIA 2,3, Pilar GARCÍA-BRONCANO 1, Cristina DIEZ 2,3, María GUZMÁN-FULGENCIO 1, Amanda FERNÁNDEZ-RODRÍGUEZ 1, Salvador RESINO 1(*)

(*) Correspondence and requests for reprints: Salvador Resino, PhD; Centro Nacional de Microbiología, Instituto de Salud Carlos III (Campus Majadahonda); Carretera Majadahonda-Pozuelo, Km 2.2; 28220 Majadahonda (Madrid); Telf.: +34 918 223 266; Fax: +34 918 223 269; e-mail: sresino@isciii.es

Affiliations: (1) Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain. (2) Unidad de Enfermedades Infecciosas/VIH; Hospital General Universitario Gregorio Marañón, Madrid, Spain. (3) Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
ABSTRACT

Transcription factor 7 like 2 (TCF7L2) rs7903146 polymorphism has been associated with metabolic disturbance and cardiovascular disease. The aim of this study was to analyze the association between TCF7L2 rs7903146 polymorphism and potential disturbances on the lipid profile in human immunodeficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients. We performed a cross-sectional study on 263 HIV/HVC-coinfected patients. TCF7L2 polymorphism was genotyped by GoldenGate assay. The analysis was performed by linear and logistic regression under a dominant model of inheritance. The variables analyzed were total cholesterol (TC), high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C), non HDL-C, and triglycerides. Patients harboring rs7903146 TT/TC genotype showed a diminished concentration of TC (p=0.003), LDL-C (p=0.004), HDL-C (p=0.012), non HDL-C (p=0.013); lower percentage of TC≥200 mg/dL (p=0.038) and higher percentage of HDL≤40 mg/dL (p=0.023). In addition, we observed that rs7903146 was differently related to fasting serum lipid levels according to HCV-genotype (HCV-GT). With regard to HCV-GT1 patients, rs7903146 TT/TC genotype was associated with lower levels of HDL-C (adjusted arithmetic mean ratio (aAMR)=0.91; p=0.049) and elevated percentage of patients with HDL-C≤40 mg/dL (adjusted odds ratio (aOR)=3.26; p=0.003). For HCV-GT3 patients, rs7903146 TT/TC genotype was associated with lower serum values of TC (aAMR=0.81; p=0.037), LDL-C (aAMR=0.67; p=0.001), non HDL-C (aAMR=0.75; p=0.002) and reduced percentage of TC≥200 mg/dL (aOR=0.089; p=0.037). In conclusion, the TCF7L2 rs7903146 TT/TC genotype was associated with lower levels of TC, LDL, and HDL in HCV-GT3 patients, and lower levels of HDL-C in HCV-GT1 patients; suggesting a role in the cardiovascular disease and a potential use as biomarker in HIV/HCV-coinfected patients.

Key words: AIDS; chronic hepatitis C; cardiovascular risk; dyslipidemia; SNPs
INTRODUCTION

Chronic hepatitis C (CHC) has become a major cause of morbimortality in human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfected patients in high-income countries (1). An increased risk of dyslipidemia, atherosclerosis and cardiovascular diseases has been associated with the HCV and HIV infections, and also with the specific antiretroviral therapies (2-6). In this way, the HCV infection has been related to steatosis and metabolic abnormalities such as insulin resistance, type 2 diabetes mellitus (T2DM), and dyslipidemia (reductions in total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) (7, 8). The coinfection with HIV modify the natural history of chronic hepatitis C (CHC), generating higher rates of liver steatosis, cirrhosis and end stage liver diseases than HCV monoinfected patients (9, 10). Although the published data suggest that combination antiretroviral therapy (cART) might be beneficial for HIV/HCV-coinfected patients (10), it has been linked to lipodystrophy, insulin resistance, type 2 diabetes mellitus, and lipid disturbances, including higher levels of TC, LDL-C, and triglyceride (TG); and decreased levels of HDL-C (11-14).

Dyslipidemia is a main risk factor of cardiovascular disease in patients with HIV infection, which is related to cART (15, 16). Thus, the risk of myocardial infarction is proportional to the time of cART (17) and it is also demonstrated that it could be partly explain by the dyslipidemia caused by these drugs (18). In this way, the increased cardiovascular risk is associated particularly with prolonged use of protease inhibitors, which are usually associated with a less favorable lipid profile, in particular elevated TG and TC (15). Moreover, nonnucleoside reverse transcriptase inhibitors show, in general, the best lipid profile of all antiretrovirals because they are associated with an increase in HDL-C and a significant reduction in TC/HDL-C ratio (15). Finally, the effects of nucleoside reverse transcriptase inhibitors on lipids are generally mild and there is a high degree of heterogeneity (11).

The mechanisms leading to lipid disturbances are not completely understood, but there is a growing evidence that genetic background may contribute to individual differences in this pathology (19-21). The transcription factor 7 like 2 (TCF7L2) is located on chromosome 10q25.3. This gene is integrated by 18 exons which suffers alternative splicing regulation. TCF7L2 is part of the Wnt/β-catenin signaling pathway, which is involved in glucose homeostasis and lipid metabolism (22). Recently, the rs7903146 (C>T) single nucleotide polymorphism (SNP) located at TCF7L2 intron 5 region, has been strongly associated with metabolic syndrome (23), type 2 diabetes mellitus (24), dyslipidemia (25) and cardiovascular disease (26, 27) in general population. However, to the best of our knowledge, the effect of TCF7L2 polymorphism has not been studied in HIV/HCV-coinfected patients.
The aim of this study was to analyze the association between TCF7L2 rs7903146 polymorphism and potential disturbances on the lipid profile in HIV/HCV-coinfected patients.
METHODS

Study design and patients

We carried out a cross-sectional study on 263 non-diabetic HIV/HCV-coinfected patients from Hospital Gregorio Marañón (Madrid, Spain) between September 2000 and July 2009. All subjects included in our study were HCV treatment-naive patients who were potential candidates for HCV therapy.

The inclusion criteria for the study were HIV/HCV-coinfected patients who were over 18 years and HCV treatment-naive, detectable HCV-RNA by polymerase chain reaction, negative hepatitis B surface antigen, availability of a DNA sample, no clinical evidence of hepatic decompensation, no diabetes mellitus, and stable cART for at least 6 months before study entry or no need for cART according to treatment guidelines used in the study period (28, 29). Patients with active opportunistic infections, pregnant women, active drug and/or alcohol addiction and other concomitant diseases or conditions were excluded. Thus, 495 HIV/HCV coinfected patients met the criteria described above, 293 of them had a DNA sample available for genotyping, but only 263 patients were included in our study (12 patients were excluded due to DNA genotyping errors and 18 due to absence of relevant clinical data). All patients were of European descent.

The study was conducted in accordance with the Declaration of Helsinki and patients gave their written consent for the study. The Institutional Review Board and the Research Ethic Committee of the Instituto de Salud Carlos III (ISCIII) approved the study.

Epidemiological and clinical data

The main clinical and epidemiological data of 263 patients analyzed were obtained from medical records. Body mass index (BMI) was calculated as the weight in kilograms divided by the square of the height in meters. The duration of HCV infection for patients with a history of intravenous drug use (IDU) was estimated starting from the first year they shared needles and other injection paraphernalia, which are the most relevant risk practices for HCV transmission (30).

Biochemical data

Biochemistry panel was measured by using an autoanalyzer Hitachi 912 (Boehringer Mannheim, Germany) in fasting patients. We collected data of TC, HDL-C, and TG. LDL-C was calculated by Friedewald estimation (LDL-C= TC - HDL-C - (TG/5)) (31). Non HDL-C was calculated as TC minus HDL-C (32). The degree of insulin resistance was estimated for each patient by using the homeostatic model assessment (HOMA), according the following formula (33): fasting plasma glucose (mmol/l) x fasting serum insulin (mU/l) / 22.5.
Liver biopsy

Liver biopsies were performed on 211 out of 263 patients basis following the recommendations of the Patient Care Committee of the American Gastroenterological Association (34) as we previously described (35). Liver fibrosis and necroinflammatory activity were estimated according to Metavir score as follows: F0, non-fibrosis; F1, mild fibrosis; F2, significant fibrosis; F3, advanced fibrosis; and F4, definite cirrhosis. Activity grade was scored as follows: A0, non-activity; A1, mild activity; A2, moderate activity; A3, severe activity (36).

Genotyping of TCF7L2 polymorphism

Genomic DNA was extracted from peripheral blood with Qiagen columns (QIAamp DNA Blood Midi/Maxi; Qiagen, Hilden, Germany). DNA samples were genotyped at the Spanish National Genotyping Center (CeGen; http://www.cegen.org/) for the rs7903146 (C>T) SNP at TCF7L2 gene using GoldenGate® assay with VeraCode® Technology (Illumina Inc. San Diego, CA, USA).

Statistical analysis

All statistical tests were performed with the Statistical Package for the Social Sciences (SPSS) 19.0 software (IBM Corp., Chicago, USA). All p-values were two-tailed and statistical significance was defined as p<0.05.

For the description of the study population, p-values were estimated with nonparametric tests: Mann-Whitney U test was used for continuous variables and Chi-square test for categorical variables.

Hardy-Weinberg equilibrium (HWE) for TCF7L2 rs7903146 polymorphism was assessed by a Chi-square test, considering equilibrium when p>0.05. The genetic association study was carried out under a dominant genetic model for T allele (CT/TT vs. CC), which was the model that best fit our data. On the one hand, lineal regression analyses were used to investigate the association between rs7903146 and continuous outcome variables, which were log10-transformed. This test provides the differences between groups and the arithmetic mean ratio (AMR), which provides us the increase of the value with presence of T allele. On the other hand, logistic regression analyses were used to investigate the association of rs7903146 with categorical outcome variables. This test gives the association between groups through the odds ratio (OR), which indicates the likelihood of having the outcome in the CT/TT genotypes versus CC genotype. Each regression analysis was always adjusted by the most significant co-variables associated with each one of the outcome variables, avoiding the over-fitting of the regression. The co-variables were selected by “Stepwise” algorithm (at each step, factors are considered for removal or entry: a p-value for entry and exit of 0.15 and 0.20,
respectively), including gender, age, body mass index (BMI), nadir CD4+ T-cells, undetectable HIV viral load (<50 copies/mL), time with cART, specific antiretroviral drugs used by each patient (zidovudine, stavudine, didanosine, tenofovir, abacavir, efavirenz, ritonavir, lopinavir, saquinavir and fosamprenavir), HCV viral load ≥500,000 IU/ml and significant fibrosis (F≥2). Besides, we also included two polymorphisms (ADIPOQ rs2241766 and SLC30A8 rs13266634), which have been related to dyslipidemia in HIV/HCV-coinfected patients, according to two recent studies (20, 21) performed by our group in the same cohort."
RESULTS

Characteristics of patients

The study included 263 patients, whose epidemiological and demographic characteristics are shown in Table 1. There were no significant differences between rs7903146 genotypes (TT/TC versus CC).

Note that patients infected with HCV-GT3 had lower serum values of TC (p=0.013), LDL-C (p=0.014), and non-HDL-C (p=0.026) than patients infected with HCV-GT1 (Supplemental Figure 1). Furthermore, liver steatosis was found in higher percentage in HCV-GT3 patients (70.6% (36/51)) than HCV-GT1 patients (52.7% (58/110); p=0.032) and HCV-GT4 patients (47.1% (16/34); p=0.029).

Frequencies of TCF7L2 polymorphism

Allele frequencies for the TCF7L2 rs7903146 polymorphism were 0.64 for C allele and 0.36 for T allele. Genotype frequencies for rs7903146 polymorphism were 0.42 for CC genotype, 0.43 for TC genotype and 0.15 for TT genotype. These frequencies in our dataset were in accordance with data listed on the NCBI SNP database (http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=7903146). The rs7903146 SNP fulfilled the minimum allele frequency (MAF)>0.05 and displayed less than 5% of missing values. Furthermore, rs7903146 was in Hardy-Weinberg equilibrium (p=0.396).

Association of rs7903146 with lipids profile

Patients with rs7903146 TT/TC genotype showed significantly lower TC serum levels (p=0.003; Figure 1A), LDL-C (p=0.004; Figure 1B), HDL-C (p=0.012; Figure 1C), and non-HDL-C (p=0.013; Figure 1D) than CC carriers. When we stratified the patients by HCV genotype, rs7903146 TT/TC carriers infected with HCV-GT3 had diminished values of TC (p=0.019; Figure 1A), LDL-C (p=0.013; Figure 1B), and non-HDL-C (p=0.020; Figure 1D).

Patients with rs7903146 TT/TC genotype had diminished percentage of TC≥200 mg/dL (p=0.038; Figure 2A) and non-HDL-C≥130 mg/dL (p=0.041; Figure 2D) and elevated percentage of HDL-C≤40 mg/dL (p=0.028; Figure 2C). When patients were stratified by HCV genotype, rs7903146 TT/TC carriers infected with HCV-GT3 had lower percentage of TC≥200 mg/dL (p=0.001. Figure 2A), whereas rs7903146 TT/TC carriers infected with HCV-GT1 had a higher percentage of HDL-C≤40 mg/dL (p=0.018; Figure 2C).

When adjusted regression was performed (Table 2), rs7903146 TT/TC carriers infected with HCV-GT3 were associated with lower values of TC (adjusted AMR (aAMR)=0.81; p=0.003), LDL-C (aAMR=0.67; p=0.001), non-HDL-C (aAMR=0.75; p=0.002); and percentage of
TC≥200 mg/dL (adjusted OR (aOR)=0.89; p=0.037). An association between rs7903146 TT/TC genotype and diminished levels of HDL-C (aAMR=0.91; p=0.049) and elevated percentage of HDL-C≤40 mg/dL (aOR)=3.26; p=0.003) were found in HCV-GT1 patents.
DISCUSSION

In the present study, we evaluated for the first time the impact of the TCF7L2 rs7903146 polymorphism on serum lipid profile in HIV/HCV-coinfected patients. The major findings were: (i) the rs7903146 TT/TC genotype (T allele) was related to lower fasting serum levels of TC, LDL-C and non HDL-C in HIV patients coinfected with HCV-GT3; (ii) rs7903146 TT/TC genotype was linked to diminished levels of HDL-C and elevated percentage of patients with HDL-C≤40 mg/dL among HIV patients coinfected with HCV-GT1.

Several reports have analyzed the TCF7L2 polymorphism association with serum lipid disturbances in non-HIV/HCV-coinfected population, providing discordant results. Thus, the presence of rs7903146 T allele disrupted the lipid metabolism, inducing low levels of HDL-C and apolipoprotein (Apo)-A1 in healthy young men (25), high levels of TG in familial combined hyperlipidaemia patients (37) and atherogenic lipoprotein profile in nonalcoholic fatty liver disease (38). Moreover, rs7903146 T allele has been linked to severity of coronary artery disease, higher death ratio by cardiovascular event and increased cardiovascular risk in non-diabetic individuals (39). In contrast, it has been described that rs7903146 T carriers show a favorable lipid profile with lower TG and higher HDL-C concentration (40). However, other studies did not find significant association between rs7903146 and lipid metabolism (41, 42). These inconsistencies could be due to different study designs (transversal, retrospective, cohorts, etc.), patient characteristics (age, race, etc.), environmental exposure (mainly diet), or underlying comorbidities (polycystic ovary syndrome, metabolic syndrome, type 2 diabetes mellitus, etc).

The cardiovascular risk and atherosclerosis associated to CHC infection have been previously reported. For instance, HCV infection has related with carotid atherosclerosis, coronary artery stenosis and increased carotid intima-media thickness (43). According to the National Cholesterol Education Program Adult Treatment Plan Guideline III (NCEP ATP-III), the evaluation of total cholesterol, triglycerides, lipoproteins and several risk factors are useful to assess the person’s risk status for CHD (44). Elevated LDL-C is considered as a major risk factor. For this reason, this is the primary target of cholesterol-lowering therapy. Patients with CHD or equivalent risks should be treated for reaching a LDL <100 mg/dL (44).

Nevertheless, the adequate interpretation of our data in the context of cardiovascular risk in coinfected patients is complicated, due to interactions between HIV, HCV and cART. For instance: (i) HIV infection is strongly related with lipid disturbances in cART-naïve patients, including reduced levels of TC, HDL-C and LDL-C, and elevated TG levels (45); (ii) cART induces increased levels of TC, LDL-C, and TG (13); (iii) HCV replication depends on lipid metabolism of host cells, which generates an increased lipid cellular content, membrane structures alterations and induces dyslipidemia, mainly represented by low circulating levels of
TC, LDL-C (2, 46) and HDL-C (46). For these reasons, we consider that the multivariate regression with continuous values of TC and lipoproteins could be a better indicator than thresholds to evaluate the impact of TCF7L2 polymorphism on relative cardiovascular risk in HIV/HCV-coinfected patients.

It is previously described that patients with CHC have a lipid profile similar to familiar hypobetalipoproteinemia. These diminished levels on beta-lipoproteins are more commonly present in HCV-GT3 infection than HCV-GT1 (47). These facts are in agreement to our results, which reveal a key role of the rs7903146 polymorphism on beta-lipoprotein metabolism in patients infected with HCV-GT3. We observed that the presence of minor T allele at rs7903146 polymorphism was associated with a favorable cardiovascular profile represented by diminished serum levels of TC, non HDL-C and LDL-C among HCV-GT3 patients. In contrast, the rs7903146 T allele was correlated with lower levels of HDL-C and an elevated percentage of patients with T allele showed HDL-C≤40 mg/dL among the HCV-GT1 patients, which is considered as an independent risk factor by NCEP ATP-III (44).

Considering that the presence of the rs7903146 T allele was related with dislipidemia, the genotyping of TCF7L2 rs7903146 polymorphism could help to identify the individuals with lipid disturbances, opening the possibility to implement early treatment for these patients. However, the analysis of rs7903146 T allele for prediction of dyslipidemia according the NCEP ATP-III thresholds revealed a low diagnostic performance [area under the receiver operating characteristic curves (AUC-ROCs) <0.6 (data not shown)]. Thus, the utility of the rs7903146 polymorphism for prediction of dyslipidemia is limited according to our data, even though further extensive clinical research studies will be needed to clarify the impact of this SNP on cardiovascular disease of HIV/HCV coinfected patients.

Many studies have described the interaction of HIV, HCV infection, and antiretroviral therapy to increase the risk of insulin resistance and T2DM (48, 49), although the mechanisms are not completely understood. Moreover, there is growing evidence that genetic background may contribute to differences between individuals in complex diseases (19, 50). A strong association between T2DM risk and TCF7L2 SNPs was reported by Grant et.al. (51). Next, genetic variations in TCF7L2 (particularly rs7903146) were related to T2DM (52) and glucose metabolism (53, 54). Later, the association between minor T allele of rs7903146 and T2DM was replicated in multiple different populations, as it is shown in independent meta-analyses by Cauchi et al. (55), Luo et al. (56), Tong et al. (57) and Peng et al. (24). Furthermore, T allele has been associated with increased proinsulin/insulin ratio, impaired beta cell function and hyperglycemia (54, 58-60). The participants of the present study were non diabetic HIV/HCV patients, but 34.6% showed insulin resistance (HOMA≥3.0). Nevertheless, an exhaustive analysis showed that the rs7903146 polymorphism was not related to HOMA values
in our HIV/HCV coinfected population (data nor shown). This lack of association with glucose metabolism could be due to the limited number of patients used in the stratified analysis, or also to the possible distortive effect of direct and indirect factors related to both HIV and HCV infections, and cART (48). Moreover, we must not discount the fact that our patients had a relatively low BMI (median: 22.5 kg/m2).

The present study has several limitations that must be taken into account for the correct interpretation of the data: (i) this is a cross-sectional study with a limited number of patients, which could limit achieving statistically significant; (ii) lipid disturbances may be caused by several interacting genetic and environmental determinants, being complicated to find the true individual effects of each disease-associated factor; (iii) our study must also be performed in monoinfected and untreated patients in order to evaluate the effect of chronic hepatitis C, HIV infection and cART separately; (iv) our study was carried out entirely in Caucasians, therefore as the allele frequency differs among ethnicities (24), it would be necessary to perform an independent replication of this study in different ethnicities.

CONCLUSIONS

The TCF7L2 rs7903146 TT/TC genotype was associated with lower levels of TC, LDL, and HDL in HCV-GT3 patients, and lower levels of HDL-C in HCV-GT1 patients; suggesting a role in the cardiovascular disease and a potential use as biomarker in HIV/HCV-coinfected patients. Nevertheless, we consider that further analyses on a large population are needed to conclusively corroborate these results.
ACKNOWLEDGEMENTS

Acknowledgements: The authors thank the Spanish National Genotyping Center (CeGen) for providing the SNP genotyping services (http://www.cegen.org).
REFERENCES


STATEMENT OF INTERESTS

Authorship Statement: The authors listed on the title page have contributed significantly to the work. The authors have nothing to disclose. The authors do not have any commercial or other association that might pose a conflict of interest.

Personal Interest: DPT, MAJS, and MGA have received research funding from “Instituto de Salud Carlos III” [grant numbers CM12/00043, CM10/00105, and CD12/00442, respectively]. JB is an investigator from the Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS).

Funding Interest: This work has been supported by grants given by Fondo de Investigación de Sanidad en España (FIS) [Spanish Health Founds for Research] [grant numbers PI08/0738, PI11/00245; PI08/0928, and PI11/01556], and “Fundación para la Investigación y la Prevención del Sida en España” (FIPSE) [grant number 361020/10]. This work has been (partially) funded by the RD12/0017/0024 and RD12/0017/0004 projects as part of the Plan Nacional R + D + I and cofinanced by ISCIII- Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER).
Table 1. Clinical and epidemiological characteristics of all HIV/HCV-coinfected patients stratified by TCF7L2 genotype. Categorical variables were expressed in absolute numbers (%). Continuous variables were expressed in median (percentile 25; percentile 75).

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>All Patients</th>
<th>TT/TC</th>
<th>CC</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>263 (100%)</td>
<td>152 (57.6%)</td>
<td>111 (42.1%)</td>
<td>-</td>
</tr>
<tr>
<td>Male</td>
<td>197 (74.9%)</td>
<td>117 (77%)</td>
<td>80 (72.1%)</td>
<td>0.365</td>
</tr>
<tr>
<td>Age, years</td>
<td>40.8 (37.9; 44.7)</td>
<td>41.2 (38.2; 44.7)</td>
<td>40.2 (37.5; 44.8)</td>
<td>0.280</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>22.5 (20.9; 24.7)</td>
<td>22.3 (20.8; 24.5)</td>
<td>22.9 (21.5; 25.1)</td>
<td>0.142</td>
</tr>
<tr>
<td>BMI ≥25 kg/m²</td>
<td>61 (23.3%)</td>
<td>33 (21.9%)</td>
<td>28 (25.9%)</td>
<td>0.527</td>
</tr>
<tr>
<td>HOMA</td>
<td>2.1 (1.3; 3.7)</td>
<td>2 (1.3; 3.8)</td>
<td>2.3 (1.3; 3.5)</td>
<td>0.215</td>
</tr>
<tr>
<td>HOMA ≥3</td>
<td>91 (34.6%)</td>
<td>51 (33.6%)</td>
<td>40 (36%)</td>
<td>0.676</td>
</tr>
<tr>
<td>Years since HCV infection</td>
<td>20.9 (14.6; 24.4)</td>
<td>20.7 (15.4; 25.1)</td>
<td>21.7 (17.5; 24.0)</td>
<td>0.904</td>
</tr>
<tr>
<td>Prior AIDS</td>
<td>77 (29.3%)</td>
<td>48 (31.6%)</td>
<td>29 (26.1%)</td>
<td>0.337</td>
</tr>
<tr>
<td>cART</td>
<td>222 (84.4%)</td>
<td>130 (85.5%)</td>
<td>92 (82.9%)</td>
<td>0.559</td>
</tr>
<tr>
<td>Time on cART, years</td>
<td>4.7 (2.9; 7.8)</td>
<td>4.9 (3; 8)</td>
<td>4.7 (2.5; 7.4)</td>
<td>0.235</td>
</tr>
</tbody>
</table>

Antiretroviral drugs

| Zidovudine                                            | 72 (27.4%)   | 42 (27.6%)   | 30 (27%)    | 0.914   |
| Stavudine                                             | 67 (25.5%)   | 38 (25.0%)   | 29 (26.1%)  | 0.836   |
| Didanosine                                            | 43 (16.3%)   | 21 (13.8%)   | 22 (19.8%)  | 0.193   |
| Tenofovir                                             | 72 (27.4%)   | 43 (28.3%)   | 29 (26.1%)  | 0.698   |
| Abacavir                                              | 43 (16.3%)   | 25 (16.4%)   | 18 (16.2%)  | 0.960   |
| Efavirenz                                             | 80 (30.4%)   | 48 (31.6%)   | 32 (28.8%)  | 0.632   |
| Ritonavir (r)                                         | 16 (6.1%)    | 12 (7.9%)    | 4 (3.6%)    | 0.150   |
| Lopinavir/ritonavir                                   | 32 (12.2%)   | 17 (11.2%)   | 15 (13.5%)  | 0.568   |
| Saquinavir                                            | 3 (1.1%)     | 1 (0.7%)     | 2 (1.8%)    | 0.388   |
| Fosamprenavir                                         | 6 (2.3%)     | 3 (2.0%)     | 3 (2.7%)    | 0.696   |

HIV markers

| Nadir CD4+, cells/μL                                   | 208 (92.3; 314.8) | 191.5 (93.8; 301.5) | 228 (83; 349) | 0.351 |
| Nadir CD4+ <200 cells/μL                               | 128 (48.7%) | 80 (52.6%) | 48 (43.2%) | 0.132 |
| CD4+ T, cells/μL                                      | 462 (338; 667) | 464.5 (323; 657.8) | 461 (363; 684) | 0.688 |
| CD4+ ≥500 cells/μL                                    | 113 (43.1%) | 67 (44.1%) | 46 (41.8%) | 0.715 |
| HIV-RNA <50 copies/mL                                 | 202 (77.1%) | 112 (73.7%) | 90 (81.8%) | 0.122 |

HCV markers, n (%)

| HCV-GT 1                                              | 142 (55.7%) | 83 (56.8%) | 59 (54.6%) | 0.665 |
| HCV-GT 2                                              | 5 (2%)     | 4 (2.7%)   | 1 (0.9%)   | 0.299 |
| HCV-GT 3                                              | 65 (25.5%) | 38 (26%)   | 27 (24.8%) | 0.820 |
| HCV-GT 4                                              | 43 (16.8%) | 21 (14.4%) | 22 (20.2%) | 0.221 |
| HCV-RNA ≥500.000 IU/ml                                | 189 (75.3%) | 110 (75.9%) | 79 (74.5%) | 0.809 |

Metavir score

| Liver biopsy patients                                 | 211 (80.3%) | 119 (93%) | 92 (92%) | 0.782 |
| Significant fibrosis (F≥2)                            | 103 (48.8%) | 52 (43.7%) | 51 (55.4%) | 0.092 |
| Moderate activity (A≥2)                               | 108 (51.9%) | 56 (47.5%) | 52 (57.8%) | 0.140 |

**Abbreviations:** AIDS, acquired immunodeficiency syndrome; BMI, body mass index; cART, combination antiretroviral therapy; HCV, hepatitis C virus; HCV-RNA, HCV plasma viral load; GT, genotype; HIV, human immunodeficiency virus; HIV-RNA, HIV plasma viral load; HOMA, homeostatic model assessment; IVDU, intravenous drug users; NNRTI, no nucleoside analog reverse-transcriptase inhibitors; NRTI, nucleoside analog reverse-transcriptase inhibitors; PI, protease inhibitors.
Table 2. Summary of adjusted association between rs7903146 TT/TC genotype and lipid profile stratified by HCV genotype in HIV/HCV coinfected patients.

<table>
<thead>
<tr>
<th>Concentration</th>
<th>All Patients</th>
<th>HCV-GT1</th>
<th>HCV-GT3</th>
<th>HCV-GT4</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AMR (95% CI)</td>
<td>p-value</td>
<td>AMR (95% CI)</td>
<td>p-value</td>
</tr>
<tr>
<td>TC, mg/dL</td>
<td>0.91 (0.84; 0.97)</td>
<td>0.006</td>
<td>0.93 (0.85; 1.02)</td>
<td>0.133</td>
</tr>
<tr>
<td>LDL-C, mg/dL</td>
<td>0.88 (0.79; 0.98)</td>
<td>0.016</td>
<td>0.93 (0.81; 1.06)</td>
<td>0.263</td>
</tr>
<tr>
<td>HDL-C, mg/dL</td>
<td>0.91 (0.84; 0.98)</td>
<td>0.012</td>
<td>0.91 (0.82; 1.00)</td>
<td>0.049</td>
</tr>
<tr>
<td>Non HDL-C, mg/dL</td>
<td>0.90 (0.82; 0.98)</td>
<td>0.016</td>
<td>0.94 (0.84; 1.05)</td>
<td>0.255</td>
</tr>
<tr>
<td>TG, mg/dL</td>
<td>0.99 (0.91; 1.10)</td>
<td>0.925</td>
<td>1.00 (0.89; 1.13)</td>
<td>0.970</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ATP III Classification</th>
<th>OR (95% CI)</th>
<th>p-value</th>
<th>OR (95% CI)</th>
<th>p-value</th>
<th>OR (95% CI)</th>
<th>p-value</th>
<th>OR (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>TC ≥200 mg/dL</td>
<td>0.49 (0.21; 1.09)</td>
<td>0.079</td>
<td>1.01 (0.34; 2.99)</td>
<td>0.983</td>
<td>0.89 (0.09-0.86)</td>
<td>0.037</td>
<td>0.47 (0.06; 3.38)</td>
<td>0.450</td>
</tr>
<tr>
<td>LDL-C ≥100 mg/dL</td>
<td>0.77 (0.44; 1.37)</td>
<td>0.374</td>
<td>0.86 (0.40; 1.88)</td>
<td>0.707</td>
<td>0.77 (0.21; 2.83)</td>
<td>0.690</td>
<td>1.72 (0.39; 7.65)</td>
<td>0.475</td>
</tr>
<tr>
<td>HDL-C ≤40 mg/dL</td>
<td>1.96 (1.15-3.36)</td>
<td>0.014</td>
<td>3.26 (1.49-7.16)</td>
<td>0.003</td>
<td>1.72 (0.53-5.55)</td>
<td>0.364</td>
<td>2.05 (0.41-10.12)</td>
<td>0.380</td>
</tr>
<tr>
<td>Non HDL-C ≥130 mg/dL</td>
<td>0.61 (0.35-1.07)</td>
<td>0.087</td>
<td>0.71 (0.34-1.47)</td>
<td>0.360</td>
<td>0.62 (0.17-2.21)</td>
<td>0.464</td>
<td>0.61 (0.15-2.45)</td>
<td>0.487</td>
</tr>
<tr>
<td>TG ≥150 mg/dL</td>
<td>0.59 (0.33-1.04)</td>
<td>0.067</td>
<td>0.72 (0.33-1.55)</td>
<td>0.399</td>
<td>0.27 (0.06-1.23)</td>
<td>0.091</td>
<td>0.16 (0.02-1.30)</td>
<td>0.087</td>
</tr>
</tbody>
</table>

(a), Multivariate lineal regression was performed to compare the serum lipid values, which were log10-transformed; (b), Logistic regression was performed to compare categorical variables. Both tests were adjusted by significant epidemiological and clinical factors [age, gender, BMI, nadir CD4+, CD4+ T cells/µL, HIV plasma viral load, HCV plasma viral load, time on CART, specific antiretroviral drugs and related SNPs]. Statistically significant differences are shown in bold.

**Abbreviations:** AMR, arithmetic mean ratio (how many times greater is the value in the presence of TT/TC genotype versus CC genotype); OR, odds ratio (likelihood of having the outcome in the CT/TT genotype versus CC genotype); CI, confidence interval; GT, genotype; HCV, hepatitis C virus; HDL-C, High-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides.
Figure 1. Summary of the unadjusted association between TCF7L2 rs7903146 and the concentration of serum lipid profile among HIV/HCV-coinfection. Variables were expressed in median (interquartile range). P-values were calculated by univariate linear regressions. Statistically significant differences were shown in bold.

Abbreviations: GT, genotype; HCV, hepatitis C virus; HDL-C, High-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

Figure 2. Summary of the unadjusted association between TCF7L2 rs7903146 and the NCEP ATP-III characteristics among HIV/HCV-coinfection. Variables were expressed in percentages. P-values were calculated by univariate logistic regressions. Statistically significant differences were shown in bold.

Abbreviations: GT, genotype; HCV, hepatitis C virus; HDL-C, High-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

Supplemental Figure 1. Serum lipid profile in HIV/HCV coinfected patients according to HCV genotype. Variables were expressed in median (interquartile range). P-values were calculated by Mann Whitney U test. Statistically significant differences were shown in bold.

Abbreviations: GT, genotype; HCV, hepatitis C virus; HDL-C, High-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.